Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-OSA 1
NCT07823608Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 3 trial of berobenatide in obstructive sleep apnea (OSA), obesity, Overweight, sponsored by Pfizer. Started Sep 2026; status: recruiting.
02
Drugs
berobenatide
03
Conditions
obstructive sleep apnea (OSA)obesityOverweight
Beyond the preview
Go deeper on NCT07823608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07823608.